Identification of preoptic sleep neurons using retrograde labelling and gene profiling

Shinjai Chung1, Franz Weber1, Peng Zhong1, Chan Lek Tan2, Thuc Nghí Nguyen3, Kevin T. Beier4, Nikolai Hörmann1, Wei-Cheng Chang5, Zhe Zhang1, Johnny Phong Do1, Shengjin Yao3, Michael J. Krashes5,6, Bosiljka Tasic3, Ali Cetin1, Hongkui Zeng3, Zachary A. Knight2, Liqun Luo4 & Yang Dan1

In humans and other mammalian species, lesions in the preoptic area of the hypothalamus cause profound sleep impairment1−5, indicating a crucial role of the preoptic area in sleep generation. However, the underlying circuit mechanism remains poorly understood. Electrophysiological recordings and c-Fos immunohistochemistry have shown the existence of sleep-active neurons in the preoptic area, especially in the ventrolateral preoptic area and median preoptic nucleus6−9. Pharmacogenetic activation of c-Fos-labelled sleep-active neurons has been shown to induce sleep10. However, the sleep-active neurons are spatially intermingled with wake-active neurons6,7, making it difficult to target the sleep neurons specifically for circuit analysis. Here we identify a population of preoptic area sleep neurons on the basis of their projection target and discover their molecular markers. Using a lentivirus expressing channelrhodopsin-2 or a light-activated chloride channel for retrograde labelling, bidirectional optogenetic manipulation, and optrode recording, we show that the preoptic area GABAergic neurons projecting to the tuberomammillary nucleus are both sleep active and sleep promoting. Furthermore, translating ribosome affinity purification and single-cell RNA sequencing identify candidate markers for these neurons, and optogenetic and pharmacogenetic manipulations demonstrate that several peptide markers (cholecystokinin, corticotropin-releasing hormone, and tachykinin 1) label sleep-promoting neurons. Together, these findings provide easy genetic access to sleep-promoting preoptic area neurons and a valuable entry point for dissecting the sleep control circuit.

Sleep-active preoptic area (POA) GABAergic (γ-aminobutyric-acid-releasing) neurons labelled by c-Fos immunohistochemistry project to the wake-promoting, histaminergic tuberomammillary nucleus (TMN) in the posterior hypothalamus8,10,11 (Extended Data Figs 1 and 2). This inhibitory projection is important for sleep generation, since insomnia induced by POA lesion is reversed by muscimol injection into the posterior hypothalamus8. To test whether this projection can be used to single out the sleep-promoting neurons, we used a lentivirus pseudotyped with the rabies glycoprotein for retrograde labelling12. Injection of the lentivirus with Cre-dependent expression of channelrhodopsin-2 fused with enhanced yellow fluorescent protein (rEIAV-DIO-TLoop-ChR2–eYFP) into the TMN of GAD2-Cre mice led to eYFP labelling of GABAergic neurons in the POA (including the ventrolateral POA, lateral POA, and the lateral part of medial POA), most of which expressed c-Fos following sleep rebound (73.6 ± 4.8%; Extended Data Fig. 2h, i). These labelled neurons are referred to as GABAPOA→TMN neurons.

To test the causal role of GABAPOA→TMN neurons in sleep regulation, we optogenetically activated them in freely moving mice. Laser stimulation (2, 5 or 10 Hz, 2 min per trial) was applied every 15−25 min, and wakefulness, rapid eye movement (REM) and non-REM (NREM) states were classified on the basis of electroencephalogram (EEG) and electromyogram (EMG) recordings (Fig. 1a). GABAPOA→TMN neuron activation caused an immediate increase in NREM sleep and a delayed increase in REM sleep at the expense of wakefulness (Fig. 1b, c, d, e, f).

Figure 1 | Optogenetic activation or inhibition of GABAPOA→TMN neurons enhances or suppresses sleep. a, Schematic of optogenetic activation experiment. Right: fluorescence image of POA (box in schematic) in a GAD2-Cre mouse with rEIAV-DIO-TLoop-ChR2–eYFP injected into the TMN. Mouse brain figure adapted with permission from ref. 31. b, Two example trials. Shown are EEG power spectra, EMG traces, brain states (colour coded), and EEG, EMG traces during selected periods (indicated by boxes) on an expanded timescale. Blue shading, laser stimulation (10 Hz, 120 s). Freq., frequency. c, Percentage of time in NREM, REM, or wake state before, during, and after laser stimulation (blue shading), averaged from nine mice (P < 0.0001 for laser-induced change from wake to sleep states, bootstrap). d, Schematic of optogenetic inhibition experiment. e, Two example trials. Blue shading, laser stimulation (constant light, 60 s). f, Percentage of time in NREM, REM, or wake state before, during, and after laser stimulation, averaged from four mice (P < 0.0001 for wake, P = 0.003 and 0.002 for REM and NREM, bootstrap). Shading for each trace, 95% confidence interval.
Optogenetic activation of GABA<sub>POA</sub> or VGLUT<sub>POA→TMN</sub> neurons promotes wakefulness. a, Schematic for optogenetic stimulation of GABA<sub>POA</sub> neurons. Mouse brain figure adapted with permission from ref. 31. b, Two example trials. Blue shading, laser stimulation (10 Hz, 120 s). c, Percentage of time in NREM, REM, or wake state, averaged from five mice ($P < 0.0001$ for increased wakefulness, bootstrap). Shading, 95% confidence interval. d–f, Similar to a–c, for optogenetic stimulation of VGLUT<sub>POA→TMN</sub> neurons ($P < 0.0001$ for increase in wakefulness, bootstrap, $n = 4$ mice).

Extended Data Fig. 3a–c and Supplementary Video 1). Activating the axons of POA GABAergic (GABA<sub>POA</sub>) neurons (infected by adenoviral vector AAV-DIO-ChR2–eYFP) projecting into the TMN also increased REM and NREM sleep and decreased wakefulness (Extended Data Fig. 4a–g), which could be partly mediated by reduced histamine release (Extended Data Fig. 4h–k). In contrast, inactivating these axons through light-activated chloride channel (iC<sub>Cl</sub>+) caused an immediate, long-lasting increase in wakefulness (Extended Data Fig. 2a, b), which could be partly mediated by reduced histamine release (Extended Data Fig. 2c–f).

On the basis of the brain state probability alone (Fig. 1c), however, it is difficult to determine whether the neuronal activity initiates or maintains a particular state, and whether the increased REM sleep results directly from laser stimulation or secondarily from increased NREM sleep, given that animals normally enter REM from NREM sleep. We thus analysed the probability of transitions between each pair of brain states (Extended Data Fig. 5). Laser stimulation of GABA<sub>POA→TMN</sub> neurons significantly enhanced wake→NREM and NREM→REM transitions but decreased wake→wake, NREM→wake, and NREM→NREM transitions, indicating that activating these neurons enhanced the initiation of both NREM and REM sleep. It also increased REM→REM and reduced REM→wake transitions, indicating enhanced REM sleep maintenance.

In contrast to ChR2-mediated activation, iC<sub>Cl</sub>+-mediated silencing of GABA<sub>POA→TMN</sub> neurons strongly increased wakefulness and decreased NREM and REM sleep (Fig. 1d–f). In control mice expressing eYFP alone, laser stimulation had no effect (Extended Data Figs 3d–f and 5c), and the laser-induced changes in sleep and wakefulness were significantly different between the ChR2 and control groups ($P < 0.0001$, bootstrap) and between iC<sub>Cl</sub>+ and control mice ($P = 0.0015$).

To test whether GABA<sub>POA→TMN</sub> neurons are functionally distinct from other nearby neurons, we injected AAV-DIO-ChR2–eYFP into the POA of GAD2-Cre mice (Fig. 2a), which should infect GABAergic neurons irrespective of their projection targets. Optogenetic activation caused an immediate, long-lasting increase in wakefulness (Fig. 2b, c and Supplementary Video 2), through enhanced NREM→wake and decreased wake→NREM transitions (Extended Data Fig. 5d). Thus, although the POA GABAergic population contains both sleep- and wake-promoting neurons<sup>6,7</sup>, the effect of non-selective activation is dominated by that of the wake-promoting neurons. We also injected the ChR2-expressing lentivirus into the TMN of VGLUT2-Cre mice (Fig. 2d). Activation of VGLUT<sub>POA→TMN</sub> neurons strongly increased wakefulness (Fig. 2e, f), indicating that the sleep-promoting effect is specific to neurons that are both GABAergic and TMN projecting.

Although cFos staining suggests that many GABA<sub>POA→TMN</sub> neurons are sleep active (Extended Data Fig. 2i), c-Fos expression is also modulated by non-activity-related factors. To measure directly the spiking activity of ChR2-labelled GABA<sub>POA→TMN</sub> neurons, we performed optrode recordings in freely moving GAD2-Cre mice. High-frequency laser pulse trains (10 or 20 Hz, 5–10 ms per pulse, 1 s per train) were applied intermittently, and single units exhibiting reliable laser-evoked spiking with short latencies and low jitter were identified as GABA<sub>POA→TMN</sub> neurons (Fig. 3a–c and Extended Data Fig. 6a, b). For the 17 identified neurons, the mean firing rate was significantly higher during REM ($P = 8.5 \times 10^{-4}$, Wilcoxon signed rank test) and NREM ($P = 0.0014$) sleep than wakefulness. Individually, all 17 neurons showed higher firing rates during REM sleep than wakefulness, and 13 of them also showed higher rates during NREM sleep ($P < 0.05$,
Wilcoxon rank sum test; the remaining four cells showed no significant difference between NREM and wake states; Fig. 3d–f). Within each NREM episode, the activity increased gradually, especially during the episodes preceding REM sleep, and the firing rates were positively correlated with EEG power in the theta (4–12 Hz) and sigma (9–25 Hz) bands but negatively in the gamma (40–120 Hz) band (Extended Data Fig. 6d, e). Compared with these identified GABAPOA–TMN neurons, the 51 unidentified POA neurons showed much greater functional diversity (Fig. 3f and Extended Data Fig. 6c), including many that were maximally active during wakefulness.

To explore the circuit mechanisms regulating GABAPOA–TMN neuron activity, we mapped their monosynaptic inputs using cell-type-specific tracing the relationship between input and output (cTRIO)15. We identified inputs from the hypothalamus and amygdala (Extended Data Fig. 7a, c). Compared with these identified GABAPOA–TMN neurons, found green fluorescent protein (GFP)-labelled presynaptic neurons received fewer inputs from the striatum, midbrain, and pons, but more inputs from the hypothalamus and amygdala (Extended Data Fig. 7c). To reveal their collateral projections to other brain areas, we expressed membrane-bound GFP (mGFP) and synaptophysin–mRuby (SYP–mRuby) in GABAPOA–TMN neurons. In addition to the TMN, GABAPOA–TMN neurons project to several brain areas and probably form local synapses within the POA (Extended Data Fig. 7d–f), suggesting that multiple pathways may contribute to their sleep-promoting effects.

To gain easier genetic access to GABAPOA–TMN neurons without relying on retrograde viruses, we next set out to identify their molecular markers. First, we used translating ribosome affinity purification (TRAP)16 (Fig. 4a and Extended Data Fig. 8a). RNA sequencing (RNA-seq) revealed multiple genes enriched in immunoprecipitated POA TMN neurons, because they play important roles in behavioural regulation.
and have proved to be useful markers for specific cell types. Among the highly enriched neuropeptides (Supplementary Table 2), we closely examined corticotropin-releasing hormone (CRH) and cholecystokinin (CCK), both of which have been implicated in sleep regulation. Immunohistochemistry showed that CCK and CRH are expressed in partly overlapping subsets of GABA<sup>POA→TMN</sup> neurons (Fig. 4b, e and Extended Data Fig. 8e–m).

We then tested whether CCK- or CRH-expressing POA neurons promote sleep. In CCK- and CRH-Cre mice<sup>19</sup> injected with AAV-DIO-ChR2–eYFP into the POA (Fig. 4c, f), laser stimulation significantly decreased wakefulness and increased NREM and REM sleep (Fig. 4d, g and Supplementary Video 3) by enhancing both the initiation and maintenance of the sleep states (Extended Data Fig. 9a, b). Furthermore, we pharmacogenetically inhibited these neurons by injecting AAV-FLEX-hM4D(Gi)–mCherry into the POA of CCK- or CRH-Cre mice<sup>20</sup> (Extended Data Fig. 10a, b). Compared with vehicle injection, clozapine-N-oxide (CNO) injection reduced REM and NREM sleep and increased wakefulness in mice expressing H4M4D(Gi) but not in control mice (Extended Data Fig. 10a, b). iC<sup>+</sup>+–mediated silencing of CCK neurons also reduced REM and NREM sleep and increased wakefulness (Extended Data Fig. 10d).

Notably, we also found significant enrichment of galanin (GAL; Supplementary Table 2), a neuropeptide highly expressed in ventrolateral POA sleep-active neurons<sup>15,21</sup>. However, optogenetic activation of GAL neurons increased wakefulness and decreased sleep (Extended Data Fig. 10c). This may be because in mice and several other species, GAL is also expressed in some wake-active neurons<sup>21</sup>, and the effect of activating both groups of GAL neurons was dominated by increased wakefulness.

As a complement to TRAP, we also performed single-cell RNA-seq of GABA<sup>POA→TMN</sup> neurons labelled by rEAV-DIO-TOloop-nls–eYFP (Fig. 4a). We found high-level expression of Tact1 (Extended Data Fig. 8d). This gene encodes several tachykinin peptides including substance P, which is implicated in sleep regulation<sup>22,23</sup>. Fluorescence in situ hybridization (FISH) showed Tact1 expression in 48.4 ± 8.4% of eYFP-labelled neurons (Fig. 4h), but only in ~10% of GAD1<sup>POA</sup> neurons (Extended Data Fig. 8g), confirming its preferential labelling of GABA<sup>POA→TMN</sup> neurons. In TAC1-Cre mice injected with AAV-DIO-ChR2–eYFP in the POA (Fig. 4i), optogenetic stimulation decreased wakefulness and enhanced NREM sleep (Fig. 4j) by increasing the initiation and maintenance of NREM sleep (Extended Data Fig. 9c).

Conversely, pharmacogenetic inhibition of these neurons increased wakefulness and decreased sleep (Extended Data Fig. 10c). Another highly expressed gene is Pdyn (Extended Data Fig. 8d), which encodes several opioid peptides including dynorphin A, the infusion of which into the ventrolateral POA increases NREM sleep<sup>23</sup>. Optogenetic activation of Pdyn neurons also increased NREM sleep and decreased wakefulness (Extended Data Figs 9d, 10f). Notably, although TAC1 partly overlaps with CCK and CRH in the POA (Extended Data Fig. 8j, k, m), the effect of activating TAC1 neurons (increasing only NREM sleep) was different from activating CCK or CRH neurons (increasing both REM and NREM sleep; Fig. 4d, g). This raises the possibility that the GABA<sup>POA→TMN</sup> population consists of separate subpopulations promoting REM and NREM sleep. In addition, Tact1 and Pdyn were not identified by TRAP, and Cck and Chrh were not identified by single-cell RNA-seq. This suggests that, given the technical limitations of both methods<sup>24</sup>, using them in parallel can enhance the likelihood of identifying markers for sleep-promoting neurons.

Using optogenetic manipulation and recording, virus-mediated circuit tracing, and gene profiling, we have characterized a population of POA sleep neurons and identified their markers. Similar to previous studies<sup>9,7</sup>, we observed high functional diversity among unidentified POA neurons. In contrast, all identified GABA<sup>POA→TMN</sup> neurons were sleep active, forming a much more homogeneous subpopulation (Fig. 3).

Whereas activating VGLUT<sup>POA→TMN</sup> or GABA<sup>POA→TMN</sup> neurons induced wakefulness (Fig. 2), GABA<sup>POA→TMN</sup> neuron activation strongly enhanced sleep (Fig. 1). These results emphasize the importance of labelling with both cell-type and projection-target specificity to single out the sleep neurons from their neighbouring wake neurons.

Among the peptide markers enriched in GABA<sup>POA→TMN</sup> neurons, CCK, CRH, TAC1, and PDYN labelled POA sleep-promoting neurons (Fig. 4 and Extended Data Figs 9 and 10). All four peptides were shown to promote sleep when applied systemically<sup>17</sup>, overexpressed in specific brain regions<sup>25,26</sup>, or injected into the POA<sup>22,23</sup>. However, most POA neurons expressing these markers are likely to co-release GABA (Extended Data Fig. 8e–h). The extent to which their sleep-promoting effects are mediated by GABA versus the neuropeptides remains to be investigated. Moreover, although activation of POA→TMN GABAergic projection can enhance sleep<sup>20</sup> (Extended Data Fig. 4), the effect of activating the POA sleep neurons may not be mediated by this pathway alone. These neurons project to multiple other areas and form local connections within the POA (Extended Data Fig. 7d–i); whether and how they interact with other sleep-wake control circuits<sup>25,26</sup> remains to be elucidated. Nevertheless, identification of their molecular markers allows selective targeting of these neurons using readily available Cre mouse lines. Given the plethora of Cre-dependent viral tools and reporter mice for optogenetic/pharmacogenetic manipulations, imaging, and circuit tracing, our findings will greatly facilitate future studies of the sleep control network.

**Online Content** Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

Received 30 November 2016; accepted 6 April 2017.

Published online 17 May 2017.

1. Von Economo, C. Sleep as a problem of localization. J. Nerv. Ment. Dis. 71, 249–259 (1930).
2. Nauta, W. J. Hypothalamic regulation of sleep in rats; an experimental study. J. Neurophysiol. 9, 289–316 (1946).
3. McGinty, D. J. & Sterman, M. B. Sleep suppression after basal forebrain lesions in the cat. Science 160, 1253–1255 (1968).
4. Sallowan, M. et al. Long-lasting insomnia induced by preoptic neuron lesions and its transient reversal by muscimol injection into the posterior hypothalamus in the cat. Neuroscience 32, 669–683 (1989).
5. Lu, J., Greco, M. A., Shiromani, P. & Saper, C. B. Effect of lesions of the ventrolateral preoptic neurons during sleep and in response to sleep deprivation. J. Physiol. (Lond.) 596, 935–946 (2004).
6. Szyszuski, R., Alam, N., Steininger, T. L. & McGinty, D. Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic hypothalamic neurons in rats. Brain Res. 803, 178–188 (1998).
7. Takahashi, K., Lin, J. S. & Sakai, K. Characterization and mapping of sleep-waking specific neurons in the basal forebrain and preoptic hypothalamus in mice. Neuroscience 161, 269–292 (2009).
8. Gong, H. et al. Activation of c-fos in GABAergic neurons in the preoptic area during sleep and in response to sleep deprivation. J. Physiol. (Lond.) 596, 2150–2159 (2014).
9. Sherin, J. E., Shimomori, P. J., McCarley, R. W. & Saper, C. B. Activation of ventrolateral preoptic neurons during sleep. Science 271, 216–219 (1996).
10. Zhang, Z. et al. Neuronal ensembles sufficient for recovery sleep and the dendate actions of norepinephrine agonists. Nat. Neurosci. 18, 553–561 (2015).
11. Sherin, J. E., Elmquist, J. K., Torrealba, F. & Saper, C. B. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci. 18, 4705–4721 (1998).
12. Steininger, T. L., Gong, H., McGinty, D. & Szyszuski, R. Subregional organization of preoptic/anterior hypothalamic projections to arousal-related monoaminergic cell groups. J. Comp. Neurol. 429, 638–653 (2001).
13. Celn, A. & Callaway, E. M. Optical control of retrogradely infected neurons using drug-regulated "T Loop" lentiviral vectors. J. Neurophysiol. 111, 2150–2159 (2014).
14. Berndt, A. et al. Structural foundations of optogenetics: determinants of channelrhodopsin ion selectivity. Proc. Natl Acad. Sci. USA 113, 822–829 (2016).
15. Beier, K. T. et al. Circuit architecture of VTA dopamine neurons revealed by systematic input-output mapping. Cell 162, 622–634 (2015).
16. Heiman, M. et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 135, 735–748 (2008).
17. Mansbach, R. S. & Lorenz, D. N. Cholecystokinin (CCK-8) elicits prandial sleep in rats. Physiol. Behav. 30, 179–183 (1983).
18. Kimura, M. et al. Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol. Psychiatry 15, 154–165 (2010).
19. Taniguchi, H. et al. A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron 71, 995–1013 (2011).
20. Sternson, S. M. & Roth, B. L. Chemogenetic tools to interrogate brain functions. Annu. Rev. Neurosci. 37, 387–407 (2014).
21. Gaus, S. E., Strecker, R. E., Tate, B. A., Parker, R. A. & Saper, C. B. Ventrolateral preoptic nucleus contains sleep-active, galaninergic neurons in multiple mammalian species. Neuron 115, 285–294 (2002).
22. Zhang, G., Wang, L., Liu, H. & Zhang, J. Substance P promotes sleep in the ventrolateral preoptic area of rats. Brain Res. 1028, 225–232 (2004).
23. Greco, M. A. et al. Opioidergic projections to sleep-active neurons in the ventrolateral preoptic nucleus. Brain Res. 1245, 96–107 (2008).
24. Okaty, B. W., Sugino, K. & Nelson, S. B. A quantitative comparison of cell-type-specific microarray gene expression profiling methods in the mouse brain. PLoS ONE 6, e16493 (2011).
25. Weber, F. et al. Control of REM sleep by ventral medulla GABAergic neurons. Nature 526, 435–438 (2015).
26. Xu, M. et al. Basal forebrain circuit for sleep-wake control. Nat. Neurosci. 18, 1641–1647 (2015).
27. Jego, S. et al. Optogenetic identification of a rapid eye movement sleep modulatory circuit in the hypothalamus. Nat. Neurosci. 16, 1637–1643 (2013).
28. Van Dort, C. J. et al. Optogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep. Proc. Natl Acad. Sci. USA 112, 584–589 (2015).
29. Hayashi, Y. et al. Cells of a common developmental origin regulate REM/non-REM sleep and wakefulness in mice. Science 350, 957–961 (2015).
30. Anaclet, C. et al. The GABAergic parafacial zone is a medullary slow wave sleep-promoting center. Nat. Neurosci. 17, 1217–1224 (2014).
31. Franklin, K. B. J. & Paxinos, G. in The Mouse Brain in Stereotaxic Coordinates 3rd edn, 31–52 (Academic, 2007).

Supplementary Information is available in the online version of the paper.

Acknowledgements We thank J. Cox, L. Pinto for help with sleep recordings; A. Popescu for help with optrode recordings; C. Ma for help with FISH; D. Leib, C. Zimmerman, and D. Estandian for discussions on TRAP; K. Kao, G. Daly, M. Bikov, F. Virani, and G. Carrillo for technical assistance; and C. Koch for supporting the collaboration with the Allen Institute for Brain Science. This work was supported by a Davis Postdoctoral Fellowship (S.C.), Tourette Syndrome Association Grant (S.C.), EMBO Long-term Fellowship (F.W.), Human Frontier Science Program Fellowship (F.W.), and Howard Hughes Medical Institute (Y.D., L.L.).

Author Contributions S.C. and Y.D. conceived and designed the study, and wrote the paper. S.C. performed most of the experiments. F.W. wrote the programs for data analysis and sleep recording, and S.C. and F.W. analysed the data. P.Z. performed slice recordings. C.L.T. and Z.A.K. constructed the herpes simplex virus (HSV virus), and performed TRAP experiments. T.N., B.T., and H.Z. performed single-cell RNA-seq. K.T.B. and L.L. provided cTRIO and axon arborization analysis reagents and performed part of the input tracing experiments. N.H. and Z.Z. performed FISH. W.C.C. and J.P.D. performed part of the sleep recording. M.J.K. generated PDYN-IRES-Cre mice. S.Y. and A.C. constructed the lentivirus. Y.D. supervised all aspects of the work.

Author Information Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Correspondence and requests for materials should be addressed to Y.D. (ydan@berkeley.edu).

Reviewer Information Nature thanks M. Halassa, T. Kilduff, A. Yamanaka and the other anonymous reviewer(s) for their contribution to the peer review of this work.
For optogenetic activation/inhibition experiments, a craniotomy was made on top of the target region for optogenetic manipulation in the same surgery as for EEG and EMG implant, and 0.1–0.5 μl virus was injected into the target region using Nanojet II (Drummond Scientific) via a micropipette. We then implanted optic fibres bilaterally into the target region. Dental cement was applied to cover the exposed skull completely and to secure the implants for EEG and EMG recordings to the screws. After surgery, mice were allowed to recover for at least 2–3 weeks before experiments. For anti-histamine experiments (Extended Data Fig. 4), triprolidine (Tocris) was administered intraperitoneally at 20 mg per kg (body weight) and brain states were recorded for 3 h.

For retrograde tracing in Extended Data Fig. 1a, 0.2–0.3 μl red or green RetroBeads (Lumafluor) was injected into each target region.

For optrode recording experiments, the optrode assembly was inserted into the POA at a depth of 4.9 mm. Screws were attached to the skull for EEG recordings, and an EMG electrode was inserted into the neck musculature. The optrode assembly, screws, and EEG/EMG electrodes were secured to the skull using dental cement. These procedures are related to the results in Fig. 3 and Extended Data Fig. 6.

For rabies tracing, AAV–CAG–FLEXloxP–TVA–mCherry and AAV–CAG–FLEXloxP–RG were injected into the TMN of HDC-Cre mice. Two to three weeks later, EnVa-pseudotyped, glycoprotein-deleted, and GFP-expressing rabies viral particles (RVDg) were injected into the TMN, and mice were euthanized 1 week later. These procedures are related to the results in Extended Data Fig. 2.

For cTRIO experiments, a retrograde virus CAV–FLEXloxP–Flp (5.0 × 10^12 genome copies per millilitre) was injected into either the TMN or the PFC of GAD2-Cre mice to express Flp recombinase specifically in GABA−/−/− or GABA−/−/−/− neurons, and AAV–FLEXloxP–TVA–mCherry (2.6 × 10^12 genome copies per millilitre) and AAV–FLEXloxP–RG (1.3 × 10^12 genome copies per millilitre) were injected into the POA to express TVa (hVα2 receptor for the EnVα envelope glycoprotein)–mCherry and rabies glycoprotein in the Flp-expressing neurons. Two to three weeks later, EnVa-pseudotyped, glycoprotein-deleted, and GFP-expressing rabies viral particles (RVDg) (5.0 × 10^12 colony forming units per millilitre) were injected into the POA, and mice were euthanized 1 week later for histology. These procedures are related to the results in Extended Data Fig. 7.

For axon arborization experiments, CAV–FLEXloxP–Flp was injected into TMN, and AAV–hSyn1–FLEXloxP–mGFP–2A-synaptophysin–mRuby was injected into the POA of GAD2-Cre mice. Mice were euthanized 4–7 weeks later for histology. These procedures are related to the results in Extended Data Fig. 7.

For pharmacogenetic experiments, AAV–hSyn–FLEX–hM4DiG–mCherry was injected bilaterally into the POA. These procedures are related to the results in Extended Data Fig. 10.

For TRAP experiments, we injected Cre-inducible HSV expressing the large ribosomal subunit protein Rpl10a fused with Flag/haemagglutinin tag (HSV–LsoSTox–Flg-HaAg–Flag–Rpl10a) into the TMN of VGAT-Cre mice. After 30–45 days of survival, the POA was dissected, and ribosome immunoprecipitation was performed to pull down the messenger RNAs (mRNAs) attached to Rpl10a. These procedures are related to the results in Fig. 4 and Extended Data Fig. 8.

For single-cell RNA-seq experiments, rEIAV–DIO–TLoop–nls–eYFP was injected into the TMN of GAD2-Cre mice. Four weeks later, we dissociated eYFP-labelled POA neurons for single-cell RNA-seq. These procedures are related to the results in Fig. 4 and Extended Data Fig. 8.

For immunohistochemistry experiments, mice received a single intraventricular injection of colchicine (12 μg) 1–2 days before killing. These procedures are related to the results in Fig. 4.

The stereotaxic coordinates were as follows. TMN: anteroposterior (AP) = −2.45 mm, mediolateral (ML) 1.0 mm, dorsoventral (DV) 5.2–5.3 mm from the coritical surface; POA: AP 0.0 mm, ML 0.7 mm, DV 5.2 mm; PFC: AP = +2.0 mm, ML 0.3 mm, DV 2.3 mm; dorsomedial hypothalamus: AP = −1.8 mm, ML 0.4 mm, DV 5.2 mm; habenula: AP = −1.8 mm, ML 0.5 mm, DV 2.2 mm.
19:00 (light on at 7:00 and off at 19:00). EEG and EMG electrodes were connected to flexible recording cables via a mini-connector. EEG and EMG signals were recorded and amplified using AM Systems, digitally filtered (0.1–1.0000 Hz and 10–1.0000 Hz for EEG and EMG recordings respectively), and digitized at 600 Hz using LabView. Spectral analysis was performed using fast Fourier transform, and brain states were classified into NREM, REM, and wake states (wake: desynchronized EEG and high EMG activity; NREM: synchronized EEG with high-amplitude, low-frequency (0.5–4 Hz) activity and low EMG activity; REM: high power at the theta frequency (5–7 Hz) with high EMG activity). Brain states were classified into NREM sleep, REM sleep, and wakefulness using custom-written MATLAB software, and the classification was performed without any information about the identity of the animal or laser stimulation timing as previously described. Optogenetic manipulation. Each optic fibre (200 µm in diameter; ThorLabs) was attached through an FC/PC adaptor to a 473-nm blue laser diode (Shanghai laser), and light pulses were generated using a Master 8 (A.M.P.I.). All photo-stimulation/inhibition experiments were conducted bilaterally and fibre optic cables were connected at least 2 h before the experiments for habituation. For photo-stimulation/inhibition experiments in ChR2+, ICa+++, or eYFP-expressing mice, light pulses (10 ms pulse, 10 Hz, 4–8 mW) or step pulses (60 s) were triggered using Master 8 that provided simultaneous input into two blue lasers. In each optogenetic manipulation experiment, inter-stimulation interval for optogenetic manipulation was chosen randomly from a uniform distribution between 15 and 25 min.

Optrode recordings. Custom-made optrodes consisted of an optical fibre (200 µm in diameter) glued together with six pairs of stereotrodes. Two FeNiCr wires (Stabohlm 675, California Fine Wire) were twisted together and electroplated to an impedance of ~600 kΩ using a custom-built plating device. The optrode was attached to a driver to allow vertical movement of the optrode assembly. The optrode was slowly lowered to search for light-responsive neurons. Wires to record cortical EEG and EMG from neck musculatures were also attached for simultaneous recordings. A TDT RZ5 amplifier was used for all the recordings, signals were filtered (0.3–8 kHz) and digitized at 25 kHz. At the end of the experiment, an electrolytic lesion was made by passing a current (200 µA, 10 s) through one or two electrodes to identify the end of the recording tract.

Spikes were sorted offline on the basis of the waveform energy and the first three principal components of the spike waveform on each stereotrode channel. For single unit isolation, all channels were separated into groups and spike waveforms were identified either manually using Klusters (http://neurosuite.sourceforge.net/) or automatically using the software klustakwik (http://klustakwik.sourceforge.net/). The quality of each unit was assessed by the presence of a refractory period and quantified using isolation distance and Dtotal. Units with an isolation distance <20 and Dtotal >0.1 were discarded.

To identify ChR2-tagged neurons, laser pulse trains (10 and/or 20 Hz) were delivered intermittently every minute. A unit was identified as ChR2-expressing if spikes were evoked by laser pulses with short first-spike latency (~6 ms for all units in our sample) and the waveforms of the laser-evoked and spontaneous spikes were highly similar (correlation coefficient >0.9). Mean latency of all identified units was 6.0 ms for all regions with a correlation coefficient of all identified units was 0.99. To calculate the average firing rate of each unit in each brain state, spikes during the laser pulse trains were excluded. These procedures are related to the results in Fig. 3 and Extended Data Figs 2 and 8.

Immunohistochemistry. Mice were deeply anesthetized and transcardially perfused using PBS buffer followed by 4% paraformaldehyde in PBS. Brains were post-fixed in fixative and stored in 30% sucrose in PBS overnight for cryopreservation. Brains were then pooled, homogenized in the homogenization buffer (10 mM HEPES, pH 7.4, 150 mM KCl, 5 mM MgCl2, 100 nM calyculin A, 2 mM DTT, 4% formaldehyde), and finally incubated with a secondary antibody as described above. To examine the overlap between each peptide marker and GAD, we used CCK-, CRH-, TA1-, and PDYN-Cre mice injected with AAV-EF1α-DIO-ChR2-eYFP or AAV-EF1α-DIO-eYFP. These procedures are related to the results in Extended Data Figs 2 and 8.

硒分析. For analysis of ribas-tracing data, consecutive 60 µm coronal sections were collected and stained using Hoescht. Slides were scanned using Nanozoomer (Hamamatsu). GFP+ input neurons were counted from the forebrain to the posterior brainstem except sections adjacent to the injection sites (1 mm from the injection site), and grouped into ten regions based on Allen Mouse Brain Atlas (http://mouse.brain-map.org/static/atlas) using anatomical landmarks in the sections visualized by Hoescht staining and autofluorescence. We normalized the number of neurons in each region by the total number of input neurons in the entire brain. These procedures are related to the results in Extended Data Fig. 7.

Axon arborization analysis. Consecutive 60 µm coronal sections were collected and stained using Hoescht. Slides were scanned using a Nanozoomer (Hamamatsu). All images were acquired using identical settings and were analysed by ImageJ Software (National Institute of Health). The classification was performed without any information about the identity of the animal or laser stimulation timing as previously described. Images were background subtracted (rolling ball radius of 50 pixels), thresholded, and pixels above this threshold were interpreted as positive signals. The mGFP- or eYFP-labeled axon arborization was measured for each region and averaged across the five sections. These procedures are related to the results in Extended Data Fig. 7.

TRAP. We adapted a previously described protocol to perform TRAP experiment. Mice were euthanized at 12:00 to 14:00 and the POA was rapidly dissected on ice with a dissecting buffer (1× HBSS, 2.5 mM HEPES (pH 7.4), 4 mM NaHCO3, 35 mM glucose, 100 µg ml−1 cycloheximide). Brains from six mice were then pooled, homogenized in the homogenization buffer (10 mM HEPES (pH 7.4), 150 mM KCl, 5 mM MgCl2, 100 mM calcium, 2 mM DTT, 100 µM RNase, 100 µg ml−1 cycloheximide and protease). Homogenates were cleared by centrifugation at 2,000 g for 10 min at 4°C. The supernatant was transferred to a new tube, and 70 µl of 10% NP40 and 70 µl of 1.2-dihexylstannyle-3-phosphocholeol (DHPC, 300 mM) per milliliter of supernatant were added. This solution was mixed and then clarified at 17,000 g for 10 min at 4°C. The resulting high-speed supernatant was transferred to a new tube. This supernatant served as the input. A small amount (25 µl) was added to a new tube containing 350 µl of buffer RLT for future input RNA purification.

Immunoprecipitation was performed with an anti-Flag antibody loaded beads. The beads were washed four times using 0.15 M KCl Wash buffer (10 mM HEPES (pH 7.4), 350 mM KCl, 5 mM MgCl2, 2 mM DTT, 1% NP40, 100 µl−1 RNase, 100 µg ml−1 cycloheximide, and protease). After the final wash, the RNA was eluted by addition of buffer RLT (350 µl) to the beads on ice, the beads removed by a magnet, and the RNA purified using the RNeasy Micro Kit (Qiagen) and analysed using an Agilent 2100 Bioanalyzer. CDNA libraries for RNA-seq were prepared with Ovation RNA-Seq System V2 and Ovation Ultralow Library Systems (NuGen), and
analysed on an Illumina HiSeq 2500. Gene classification shown in Supplementary Table 1 was performed using PANTHER (http://pantherdb.org/)40. These procedures are related to the results in Fig. 4 and Extended Data Fig. 8.

**Single-cell RNA-seq.** We adapted a previously described procedure to isolate fluorescently labelled neurons from the mouse brain41–43.

**Single-cell isolation.** Individual adult male mice (postnatal day 56 ± 3) were anaesthetized in an isoflurane chamber, decapitated, and the brain was immediately removed and submerged in fresh ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM): NaCl 125, KCl 3, CaCl2 2, MgSO4 2, NaH2PO4 1.25, sodium ascorbate 1.3, sodium pyruvate 0.6, NaHCO3 26, and glucose 10, at pH 7.4. Inhibitory postsynaptic currents were recorded using a caesium-based internal solution (in mM: CsMeSO4 125, CsCl 2, HEPES 10, EGTA 0.5, MgATP 4, NaGTP 0.3, sodium phosphocreatine 10, TEACI 5, QX-314 3.5, at pH 7.3, adjusted with CsOH, 290–300 mOsM) and isolated by clamping the membrane potential of the recorded neuron at the reversal potential of the excitatory synaptic currents. The resistance of the patch pipette was 3–5 MΩ. The cells were excluded if the series resistance exceeded 40 MΩ or varied by more than 20% during the recording period. To activate ChR2, we used a mercury arc lamp (Olympus) coupled to the epifluorescence light path and bandpass filtered at 450–490 nm (Semrock), gated by an electromagnetically shutter (Uniblitz). A blue light pulse (5 ms) was delivered through a 40 × 0.8 numerical aperture water immersion lens (Olympus) at a power of 1–2 mW. Data were recorded with a Multiclamp 700B amplifier (Axon instruments) filtered at 2 kHz and digitized with a Digidata 1440A (Axon instruments) at 4 kHz. Recordings were analysed using Clampfit (Axon instruments). These procedures are related to the results in Extended Data Fig. 2.

**Single-cell reverse-transcription PCR.** At the end of each recording, cytoplasm was aspirated into the patch pipette, expelled into a PCR tube as described previously45. The single-cell reverse-transcription PCR (RT–PCR) protocol was designed to detect the presence of mRNAs coding for GAPDH, GAD1, VGLUT2, and HDC. First, reverse transcription and the first round of PCR amplification were performed with gene-specific multiplex primer using the SuperScript III One-step RT–PCR kit (12574-018, Invitrogen) according to the manufacturer’s protocol. The second, nested PCR was performed using GoTag Green Master Mix (MT121, Promega) with nested primers for each gene. Amplification products were visualized by electrophoresis using 2% agarose gel.

Primers (5′→3′) for single-cell RT–PCR were as follows. GAPDH (sense/anti-sense): multiplex, ATCCATCATCAGGCAATGTT/CAATGGGAGTGTAAGAAGC; nested, AGGGTGGTACTAAGGGGAGA/GTACTGAAGCCATCA; final product 331 base pairs (bp). VGLUT2 (sense/anti-sense): multiplex, GCCGCTACCATCATCATCATCATCAT/CGTCTCCTCCTCCTCCTC; nested, AATAGTCAACAAACGCTACACATAT/ATAGAGAGAGAGAGAGAG; final product 306 bp. HDC (sense/anti-sense): multiplex, GAGGCCCTTGTGACTACGTG/GTACCTGAGAGGTAAGCTGTT; nested, GGTTAATTAACCAACAAGCTACTGTTGC; final product 182 bp. These procedures are related to the results in Extended Data Fig. 2.

**Statistics.** Statistical analysis was performed using MATLAB, GraphPad Prism, or Python. The selection of statistical tests was based on reported previous studies. All statistical tests were two-sided. The 95% confidence intervals for brain state probabilities were calculated using a bootstrap procedure: for an experimental group of n mice, with mouse i comprising mi trials, we repeatedly resampled the data by randomly drawing for each mouse mi trials (random sampling with replacement). For each of the 10,000 iterations, we recalculated the mean probabilities for each ability were calculated using a bootstrap procedure: for an experimental group with number of animals required to reach sufficient statistical power. To determine the sample size (number of units) for optrode recordings, we first recorded from two animals. Given the success rate of finding identified units and the homogeneity of units in the initial data set, we set a target sample size. For rabbits-mediated
retr-o-gade tracing, histology, and slice recording experiments, the selection of the sample size was based on numbers reported in previous studies. For gene profiling experiments, sample size was not calculated *a priori*, and the selection of the sample size was based on previous studies. Otherwise, no statistical methods were used to predetermine sample size.

**Data availability.** The single-cell RNA-sequencing data have been deposited in the Gene Expression Omnibus under accession number GSE79108. All other data are available from the corresponding author upon reasonable request.

32. Vong, L. et al. Leptin action on GABAergic neurons prevents obesity and reduces inhibitory tone to POMC neurons. *Neuron* **71**, 142–154 (2011).
33. Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* **13**, 133–140 (2010).
34. Krashes, M. J. et al. An excitatory paraventricular nucleus to AgRP neuron circuit that drives hunger. *Nature* **507**, 238–242 (2014).
35. Terao, A., Greco, M. A., Davis, R. W., Heller, H. C. & Kilduff, T. S. Region-specific changes in immediate early gene expression in response to sleep deprivation and recovery sleep in the mouse brain. *Neuroscience* **120**, 1115–1124 (2003).
36. Börgel, A. A., Tobler, I. & Hanagasioglu, M. Effect of sleep deprivation on sleep and EEG power spectra in the rat. *Behav. Brain Res.* **14**, 171–182 (1984).
37. Anikeeva, P. et al. Optetrode: a multichannel readout for optogenetic control in freely moving mice. *Nat. Neurosci.* **15**, 163–170 (2011).
38. Schmitt-Verbeke, N., Jackson, J., Henze, D., Harris, K. & Redish, A. D. Quantitative measures of cluster quality for use in extracellular recordings. *Neuroscience* **131**, 1–11 (2005).
39. Knight, Z. A. et al. Molecular profiling of activated neurons by phosphorylated ribosome capture. *Cell* **151**, 1126–1137 (2012).
40. Mi, H., Muruganujan, A., Casagrande, J. T. & Thomas, P. D. Large-scale gene function analysis with the PANTHER classification system. *Nat. Protocols* **8**, 1551–1566 (2013).
41. Sugino, K. et al. Molecular taxonomy of major neuronal classes in the adult mouse forebrain. *Nat. Neurosci.* **9**, 99–107 (2006).
42. Hempel, C. M., Sugino, K. & Nelson, S. B. A manual method for the purification of fluorescently labeled neurons from the mammalian brain. *Nat. Protocols* **2**, 2924–2929 (2007).
43. Tasic, B. et al. Adult mouse cortical cell taxonomy revealed by single cell transcriptomics. *Nat. Neurosci.* **19**, 335–346 (2016).
44. Zhang, S. et al. Long-range and local circuits for top-down modulation of visual cortex processing. *Science* **345**, 660–665 (2014).
45. Lambolez, B., Audinat, E., Bochet, F., Crépel, F. & Rossier, J. AMPA receptor subunits expressed by single Purkinje cells. *Neuron* **9**, 247–258 (1992).
Extended Data Figure 1 | Overlap of c-Fos staining of sleep-active POA neurons with retrograde labelling from several brain regions and with GAD1–GFP or VGLUT2–GFP. a, Overlap between c-Fos expression induced by sleep rebound (Sleep, \( n = 5 \) mice) or sleep deprivation (Wake, \( n = 3 \)) and retrobead (RB) labelling from the TMN, dorsomedial hypothalamus (DMH, \( n = 3 \)), or ventrolateral periaqueductal grey (vPAG, \( n = 3 \)). Mouse brain figure adapted with permission from ref. 31. Left column, representative images showing retrobead injection sites (scale bars, 500 \( \mu \text{m} \)). Percentage of c-Fos\(^+\) neurons containing retrobead and percentage of retrobead-containing cells that were c-Fos\(^+\) were both significantly different among target regions (\( P < 0.0001 \) and \( P = 0.0004 \), one-way analysis of variance followed by Dunnett’s post-hoc test). Many retrobead-labelled neurons from TMN expressed c-Fos following sleep but not following wake. b, Overlap between c-Fos expression induced by sleep rebound and GAD1–GFP (top, five mice) or VGLUT2–GFP (bottom, three mice). Many c-Fos\(^+\) cells were GAD1\(^+\) (arrowheads). Error bar, ±s.e.m.
Extended Data Figure 2 | Innervation of histamine neurons in the TMN by GABAergic neurons in the POA and overlap of lentivirus labelling of GABA$_{\text{POA} \rightarrow \text{TMN}}$ neurons with GAD expression and with c-Fos labelling after sleep rebound. a, In GAD2-Cre mice injected with AAV-DIO-ChR2–eYFP in the POA (left), ChR2–eYFP-expressing axons (green) are observed in the TMN area (red, histidine decarboxylase (HDC)). Mouse brain figure adapted with permission from ref. 31. b, Inhibitory postsynaptic current (red) recorded in an example TMN histamine neuron, evoked by optogenetic activation of POA GABAergic axons. Light-evoked responses (red) were blocked by bicuculline (black). Blue tick, laser stimulus. c, Amplitudes and latencies of inhibitory postsynaptic currents recorded from TMN histamine neurons (n = 7, from two mice). Each symbol represents data from one cell. Error bar, ± s.e.m. d, Single-cell RT–PCR identification of HDC-expressing histamine neurons. e, Schematic of RV-mediated trans-synaptic retrograde tracing from TMN histamine neurons. Fluorescence image of the TMN shows starter cells (yellow, expressing both GFP and mCherry). Inset, enlarged view of the region in white box. f, Left, fluorescence image showing input neurons in the POA. Right, enlarged view of the region in white box, showing RV–GFP labelling (green) and GAD1/2 expression (red, FISH for mRNA encoding GAD1/2). Arrowheads, RV labelled cells that are GAD1/2$^+$. 79.0 ± 1.4% of RV–GFP labelled neurons contained mRNA encoding GAD1/2 (n = 2 mice). g, Overlap between c-Fos expression induced by sleep rebound and RV–GFP labelling. Left, fluorescence image showing input neurons in the POA. Right, enlarged view of the region in white box, showing RV–GFP labelling and c-Fos expression; 46.9 ± 1.9% of RV–GFP labelled neurons expressed c-Fos (n = 6 mice). h, Expression of eYFP or ChR2–eYFP in the POA induced by injecting rEIAV-DIO-TLoop-nls–eYFP or rEIAV-DIO-TLoop-ChR2–eYFP into the TMN of GAD2-Cre mice and their overlap with GAD1/2 expression (FISH for mRNA encoding GAD1/2). Arrowheads indicate cells co-labelled with GAD-FISH probe and eYFP or ChR2–eYFP; 96.2 ± 1.4% of eYFP-labelled neurons and 95.4 ± 3.7% of ChR2–eYFP-labelled neurons contained mRNA encoding GAD1/2 (n = 4, 5). i, Expression of ChR2–eYFP in the POA induced by injecting rEIAV-DIO-TLoop-ChR2–eYFP into the TMN of a GAD2-Cre mouse and its overlap with c-Fos expression following sleep rebound (arrowheads).
Extended Data Figure 3 | Effect of optogenetic activation of GABA<sub>POA→TMN</sub> neurons at low frequencies and effect of laser stimulation in GABA<sub>POA→TMN</sub>-eYFP control mice. a, Similar to Fig. 1, rEIAV-DIO-TLoop-ChR2-eYFP was injected into the TMN of GAD2-Cre mice and an optic fibre was implanted into the POA for optogenetic stimulation. Mouse brain figure adapted with permission from ref. 31. b, Percentage of time the mice spent in wake, NREM, or REM state before, during, and after laser stimulation (blue shading, 5 Hz, 120 s), averaged from five mice (\( P < 0.0001 \) for wake, REM, and NREM, bootstrap). c, Similar to b, but with 2 Hz stimulation (\( P < 0.0001 \) for wake and REM, \( P = 0.002 \) for NREM, bootstrap, \( n = 5 \) mice). d, Similar to a, after rEIAV-DIO-TLoop-nls-eYFP injection. e, Effect of 10 Hz stimulation in eYFP control mice. Shown is the percentage of time in wake, NREM, or REM state before, during, and after laser stimulation (blue shading, 10 Hz, 120 s), averaged from eight mice (\( P = 0.18, 0.84, \) and 0.35 for REM, NREM, and wake respectively, bootstrap). f, Effect of constant light stimulation (blue shading, constant light, 60 s), averaged from five mice (\( P = 0.57, 0.27, \) and 0.73 for REM, NREM, and wake, bootstrap). Shading for each trace, 95% confidence interval.
Extended Data Figure 4 | See next page for caption.
Extended Data Figure 4 | Optogenetic manipulation of axon projections of GABA<sup>POA</sup> neurons to TMN, dorsomedial hypothalamus, and habenula, and effect of anti-histamine on optogenetic activation of the TMN axon projections. AAV-DIO-ChR2–eYFP or AAV-DIO-iC<sup>++</sup>–eYFP was injected into the POA of GAD2-Cre mice and an optic fibre was implanted into the TMN for optogenetic activation/inhibition. Mouse brain figure adapted with permission from ref. 31. b. Percentage of time in wake, NREM, or REM state before, during, and after laser stimulation (blue shading, 10 Hz, 120 s) in mice expressing ChR2, averaged from nine mice (P < 0.0001 for wake, REM and NREM, bootstrap). Shading for each trace, 95% confidence interval. c. Similar to b, but in mice expressing iC<sup>++</sup> (blue shading: constant light, 60 s), averaged from four mice (P < 0.0001 for wake and NREM, P = 0.004 for REM, bootstrap). d. Schematic for optogenetic activation of POA GABAergic projection to the habenula (Hb). e. Similar to b, for activating POA→habenula projection (P = 0.28, 0.35 and 0.72 for REM, wake and NREM, bootstrap, n = 3 mice). f. Schematic for optogenetic activation of POA GABAergic projection to the dorsomedial hypothalamus. g. Similar to b, for POA→dorsomedial hypothalamus activation (P = 0.02, 0.12, and 0.09 for wake, REM, and NREM, n = 3 mice). h. Left, schematic for optogenetic activation of POA GABAergic projection to the TMN without drug treatment. Right, percentage of time in wake, NREM, or REM state before, during, and after laser stimulation (blue shading, 10 Hz, 120 s) in mice with no drug (effect of laser: P < 0.001 for wake, REM, and NREM, bootstrap; n = 14 mice). i. Similar to b, but after intraperitoneal injection of triprolidine (20 mg per kg (body weight); effect of laser: P = 0.21, 0.84, 0.57 for wake, REM, and NREM, n = 5 mice). j. Percentage of time in NREM, REM, or wake state before and during laser stimulation in no drug and triprolidine groups (120 s periods before and during laser stimulation, *P < 0.05, **P < 0.01, ***P < 0.001; NS, P > 0.05, signed rank test between before and during laser, rank sum test between no drug and triprolidine for the period before laser stimulation). k. Laser-induced change in the percentage of each state (difference between the 120 s periods before and during laser stimulation, *P < 0.05, rank sum test). Error bar, ±s.e.m.
Extended Data Figure 5 | See next page for caption.
Extended Data Figure 5 | Effect of laser stimulation on transition probability between each pair of brain states in GABA\textsuperscript{POA→TMN}→ChR2, GABA\textsuperscript{POA→TMN}→Ctrl, and GABA\textsuperscript{POA→ChR2} mice. a, Schematic showing transition probability calculation. To calculate the transition probability at a given time bin (i), we first identified all the trials (n) in which the animal was in state X (X could be wake, NREM, or REM) in the preceding time bin (i − 1). Among these n trials, we identified the subset of trials (m) in which the animal transitioned into state Y in the current time bin (i). The X→Y transition probability for time bin i was computed as m/n.

b, Transition probability within each 10 s period in GABA\textsuperscript{POA→TMN→ChR2} mice (n = 9). Shown in each bar is the transition probability averaged across six consecutive 10 s bins within each 60 s. Error bar, 95% confidence interval (bootstrap). The baseline transition probability (grey dashed line) was averaged across all time bins after excluding the laser stimulation period. Direct wake—REM and REM—NREM transitions were not observed and the corresponding plots were omitted. Magenta asterisk (*)/green hash symbol (#) indicates significant increase/decrease in transition probability during laser stimulation compared with the baseline (P < 0.05, bootstrap). Top right diagram indicates transition probabilities that are significantly increased (magenta), decreased (green), or unaffected (black) by laser stimulation. c, Transition probability in control mice (n = 8). The probability during laser stimulation was not significantly different from baseline for any transition. d, Transition probability in GABA\textsuperscript{POA→ChR2} mice (n = 5).
Extended Data Figure 6 | Optogenetic identification of GABA<sub>POA→TMN</sub> neurons, firing rates of unidentified POA neurons, and firing rate dynamics of identified GABA<sub>POA→TMN</sub> neurons during NREM sleep. 

**a**, Distribution of delays in laser-evoked spiking for all identified neurons. Delay was defined as timing of the first spike after each laser pulse. 

**b**, Distribution of correlation coefficient between laser-evoked and spontaneous spike waveforms for all identified neurons. 

**c**, Firing rates of unidentified units in the three brain states. Each line represents data from one neuron. Grey bar represents average over units (n = 51, from 11 mice). Error bar, ± s.e.m. 

**d**, Firing rate change of identified GABA<sub>POA→TMN</sub> neurons during each NREM episode. Top: mean EEG power spectrogram from start to end of each NREM episode. Bottom: mean firing rate of the recorded neurons. Left: average across all NREM episodes. Each NREM period was divided into ten time bins (temporally normalized). The firing rate of each neuron was z-scored and averaged across all recorded NREM episodes. Solid line, mean of 17 neurons; shading, ± s.e.m. To test significance of the firing rate increase during NREM episodes, for each unit we measured the slope of its mean firing rate versus time after NREM onset, as quantified by a linear fit. Across the 17 units recorded, the increase (slope > 0) was significant (P = 1.0 × 10<sup>−5</sup>, t-test). Middle and right: similar to left, for the subset of NREM episodes preceding wakefulness (P = 0.0089) and that preceding REM sleep (P < 10<sup>−5</sup>). The increase in firing rate was stronger for NREM episodes preceding REM sleep than those preceding wakefulness (P = 0.0003, paired t-test). 

**e**, Correlation between firing rate and EEG power in different frequency bands (delta, 0.5–4 Hz; theta, 4–12 Hz; sigma; 9–25 Hz; gamma, 40–120 Hz) during NREM sleep. The firing rate of each neuron was z-scored, and the power within each frequency band was normalized by its mean across each recording session. Firing rates and EEG power in each frequency band were discretized in 2.5 s bins. For each bin assigned to NREM sleep, we plotted the power in each frequency band versus the corresponding firing rate. Linear regression was used to determine whether the power in each frequency band and the firing rate were positively or negatively correlated. The correlation was positive for theta (P < 10<sup>−5</sup>) and sigma (P < 10<sup>−5</sup>), negative for gamma (P < 10<sup>−5</sup>), and not significant for delta (P = 0.58). 

© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Extended Data Figure 7 | Mapping of monosynaptic inputs and axon projections of GABA POA→TMN neurons and axon projections of POA CCK, CRH, TAC1 neurons. 

a, Schematic of cTRIO to map monosynaptic inputs to GABA POA→TMN (left) or GABA POA→PFC (right) neurons. Mouse brain figure adapted with permission from ref. 31. Middle, coronal section of a mouse brain at the POA stained with Hoechst (blue). A region within the square is magnified in the inset. Arrowheads indicate starter cells (yellow) at the injection site (scale bar in inset, 50 μm). b, Optogenetic activation of GABA POA→TMN neurons. Shown is the percentage of time in wake, NREM, or REM state before, during, and after laser stimulation (blue shading, 10 Hz, 120 s), averaged from six mice (P < 0.001 for wake and NREM, P = 0.003 for REM, bootstrap). Shading for each trace, 95% confidence interval. c, Average fractional inputs in cTRIO POA→TMN (purple) or cTRIO POA→PFC (grey) tracing (P = 0.0002 for hypothalamus, P = 0.02 for amygdala, P = 0.03 for striatum, P = 0.001 for midbrain, P = 0.003 for pons, t-test). N = 3 mice in each group. Error bar, ± s.e.m.

d, Schematic of the axon projection mapping experiment. e, Coronal sections containing POA, TMN, and dorsomedial hypothalamus regions stained with Hoechst (blue). A region within the square is magnified in the inset. Red, synaptophysin–mRuby; green, mGFP. f, Projection levels (quantified by mGFP-labelled axonal arbors) in different brain areas normalized by that in the TMN. Shown are only areas with projections >10% of the TMN projection. Hb, habenula; LH, lateral hypothalamus. N = 3 mice. g–i, Axon projections of POA CCK, CRH, TAC1 neurons. Top: coronal section containing the TMN region. Red, immunostaining for HDC showing histaminergic neurons. Bottom: projection levels (quantified by eYFP-labelled axonal arbors) in different brain areas normalized by that in the TMN. N = 3, 3, 4 mice respectively.
Extended Data Figure 8 | See next page for caption.
Extended Data Figure 8 | Identification of genetic markers for GABA<sup>POA→TMN</sup> neurons using TRAP and single-cell RNA-seq, and overlap between each identified marker and GAD and between the markers in the POA. a, TRAP; shown is bioanalyzer trace of immunoprecipitated RNA. FU, fluorescence units. b, Histogram display of differentially expressed genes (immunoprecipitation per input). c, Fragments per kilobase of transcript per million mapped reads (FPKM) immunoprecipitation versus FPKM input (log scale). Several marker genes enriched in GABA<sup>POA→TMN</sup> neurons (Cck, Crh, Slc32a1, Rpl10a) are highlighted. Red dots, genes that are significantly different in immunoprecipitation versus input (\(P < 0.05\), Fisher’s exact test); blue dots, non-significant genes. d, Single-cell RNA-seq; shown is heat map of expression levels of several cell-type markers (for example, Gad1, Gad2, Slc32a1, Slc17a6, and Chat) and all neuropeptide-encoding genes (on the basis of the list of ref. 43 plus GAL) in cholinergic neurons in the nucleus basalis and eYFP-labelled GABA<sup>POA→TMN</sup> neurons in the POA. Tac1 and Pdyn are highly expressed in GABA<sup>POA→TMN</sup> neurons. RPKM, reads per kilobase of transcript per million mapped reads. e–h, Overlap between each identified marker and GAD. A representative image showing overlap between CCK-ChR2–eYFP (e), CRH–eYFP (f), TAC1–eYFP (g), DYN-ChR2–eYFP (h), and FISH for mRNA encoding GAD1/2. Arrowheads indicate cells co-labelled with GAD1/2 probe and eYFP. Mouse brain figure adapted with permission from ref. 31. i–k, Overlap between the markers. A representative image showing overlap between CCK and CRH (i), CRH and TAC1 (j), or CCK and TAC1 (k) using double FISH for both peptides. Arrowheads indicate co-labelled cells. l, Percentage of cells expressing each peptide marker that are GAD1/2 positive (\(n = 2\) or 3 mice per marker). m, Quantification of overlap between CCK and CRH, TAC1 and CRH, or TAC1 and CCK (\(n = 3\) mice per pair). Error bar, ±s.e.m.
Extended Data Figure 9 | Effect of laser activation of CCK, CRH, TAC1, and PDYN neurons on transition probability between each pair of brain states. a, Transition probability within each 10 s period in CCK neuron activation experiment. Error bar, 95% confidence interval (bootstrap). N = 4 mice. b–d, Similar to a, for CRH, TAC1, and PDYN neuron activation. N = 5, 7, 5 mice, respectively.

--- Baseline
* Significant increase
# Significant decrease
Extended Data Figure 10 | See next page for caption.
Extended Data Figure 10 | Pharmacogenetic inactivation of CCK, CRH, and TAC1 neurons, optogenetic inactivation of CCK neurons, optogenetic activation of GAL neurons, and optogenetic activation of PDYN neurons in the POA. a, Pharmacogenetic inactivation of CCK neurons. Left, a representative image showing hM4D(Gi)–mCherry expression in the POA of a CCK-Cre mouse and an enlarged view of the region in white box. Mouse brain figure adapted with permission from ref. 31. Middle, effect of CNO injection in CCK-Cre mice expressing hM4D(Gi). Each bar shows the percentage of time in each brain state during the first 4 h of the recording session, after injection of vehicle (grey) or CNO (blue). Error bar, ±s.e.m. (n = 6 mice, P = 0.022, 0.025, 0.044 for REM, wake, and NREM, paired t-test). Right, effect of CNO injection in control CCK-Cre mice not expressing hM4D(Gi) (n = 4 mice, P = 0.27, 0.46, and 0.29 for REM, wake, and NREM, paired t-test). The effect of CNO was significantly different between hM4D(Gi)-expressing and control mice (P = 0.006, 0.036, and 0.014 for REM, wake, and NREM, t-test). b, Similar to a, for CRH neuron inactivation (n = 6 mice, P = 0.015, 0.018, 0.024). For control, n = 5 mice; P = 0.58, 0.41, and 0.12. Difference between hM4D(Gi) and control, P = 0.003, 0.03, and 0.014. c, For TAC1 neuron inactivation (n = 6 mice, P = 0.0057, 0.0026, 0.0095). For control, n = 4 mice; P = 0.92, 0.13, and 0.06. Difference between hM4D(Gi) and control, P = 0.001, 0.005, and 0.037. d, Optogenetic inhibition of POA CCK neurons suppresses sleep and enhances wakefulness. Shown is the percentage of time in wake, NREM, or REM state before, during, and after laser stimulation (blue shading, constant light, 60 s), averaged from four mice (P < 0.0001 for wake and NREM, P = 0.008 for REM, bootstrap). e, Similar to d, with laser stimulation of POA GAL neurons (blue shading, 10 Hz, 60 s), averaged from four mice (P < 0.0001 for increase in wakefulness, bootstrap). f, Similar to d, with optogenetic stimulation of POA PDYN neurons (blue shading, 10 Hz, 120 s), averaged from five mice (P = 0.42, 0.002, and 0.0003 for REM, NREM, and wake, bootstrap). Shading for each trace, 95% confidence interval.